138 related articles for article (PubMed ID: 34405028)
1. When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer.
Kim H; Kim H; Lee M; Kwon M; Hong JY; Lee J; Lim HY; Kang WK; Kim ST
J Cancer; 2021; 12(18):5681-5686. PubMed ID: 34405028
[No Abstract] [Full Text] [Related]
2. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
[No Abstract] [Full Text] [Related]
3. Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer.
Kim H; Kim R; Jo H; Kim HR; Hong J; Ha SY; Park JO; Kim ST
Therap Adv Gastroenterol; 2022; 15():17562848221117638. PubMed ID: 35992188
[TBL] [Abstract][Full Text] [Related]
4. Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis.
Petrelli F; Ghidini M; Ghidini A; Tomasello G
JAMA Oncol; 2020 Jul; 6(7):1068-1071. PubMed ID: 32407439
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma.
Wei J; Xiang J; Hao Y; Si J; Gu X; Xu M; Song Z
J Thorac Dis; 2023 Feb; 15(2):260-269. PubMed ID: 36910045
[TBL] [Abstract][Full Text] [Related]
6. Rational application of the first-line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta-analysis.
Cao R; Ma JT; Zhang SL; Sun L; Liu Y; Zhang XY; Jing W; Huang LT; Han CB
Cancer Med; 2019 Sep; 8(11):5033-5046. PubMed ID: 31297962
[TBL] [Abstract][Full Text] [Related]
7. Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review.
Maiorano BA; Maiorano MFP; Ciardiello D; Maglione A; Orditura M; Lorusso D; Maiello E
Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497437
[TBL] [Abstract][Full Text] [Related]
8. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes Associated with Monotherapy and Combination Therapy of Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Hepatocellular Carcinoma in Real-World Practice: A Systematic Literature Review and Meta-Analysis.
Zou H; Lei Q; Yan X; Lai Y; Ung COL; Hu H
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612256
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.
Nie C; Xu W; Guo Y; Gao X; Lv H; Chen B; Wang J; Liu Y; Zhao J; Wang S; He Y; Chen X
BMC Cancer; 2023 Dec; 23(1):1239. PubMed ID: 38102538
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
Gómez de Liaño Lista A; van Dijk N; de Velasco Oria de Rueda G; Necchi A; Lavaud P; Morales-Barrera R; Alonso Gordoa T; Maroto P; Ravaud A; Durán I; Szabados B; Castellano D; Giannatempo P; Loriot Y; Carles J; Anguera Palacios G; Lefort F; Raggi D; Gross Goupil M; Powles T; Van der Heijden MS
Eur Urol; 2020 Feb; 77(2):269-276. PubMed ID: 31699525
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma.
Guo L; Wang X; Wang S; Hua L; Song N; Hu B; Tong Z
Oncoimmunology; 2021 Mar; 10(1):1887551. PubMed ID: 33747636
[TBL] [Abstract][Full Text] [Related]
13. Does denosumab offer survival benefits? -Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors.
Cao Y; Afzal MZ; Shirai K
J Thorac Dis; 2021 Aug; 13(8):4668-4677. PubMed ID: 34527308
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
15. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
[TBL] [Abstract][Full Text] [Related]
16. A real-world study of immune checkpoint inhibitors in advanced triple-negative breast cancer.
Zhang Z; Zhang Y; Liu C; Shao J; Chen Y; Zhu Y; Zhang L; Qin B; Kong Z; Wang X; Wang Y; Huang D; Liu L; Zhou Y; Tao R; Yang Z; Liu M; Zhao W
Cancer Innov; 2023 Jun; 2(3):172-180. PubMed ID: 38089401
[TBL] [Abstract][Full Text] [Related]
17. Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials.
Facchinetti F; Di Maio M; Tiseo M
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32947924
[TBL] [Abstract][Full Text] [Related]
18. Sarcopenia Was a Poor Prognostic Predictor for Patients With Advanced Lung Cancer Treated With Immune Checkpoint Inhibitors.
Li S; Liu Z; Ren Y; Liu J; Lv S; He P; Yang Y; Sun Y; Chang J; Luo D; Cong M
Front Nutr; 2022; 9():900823. PubMed ID: 35923193
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study.
Guven DC; Aykan MB; Muglu H; Bayram E; Helvaci K; Dursun B; Celayir M; Chelebiyev E; Nayir E; Erman M; Sezer A; Urun Y; Demirci U; Er O; Disel U; Bilici A; Arslan C; Karadurmus N; Kilickap S
Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38140782
[TBL] [Abstract][Full Text] [Related]
20. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
